Pharmaceutical Associates
Pharmaceutical Associates, Inc. (PAI Pharma) is a leading provider of over 250 product NDCs, including unit-dose and liquid medicines, with a focus on oral liquid and sterile injectable products. The company operates a CGMP-compliant facility and has recently expanded its portfolio through the acquisition of VistaPharm and Teligent Inc.'s US marketing authorizations.
Company Overview
Pharmaceutical Associates Inc. (PAI Pharma) is a distinguished player in the pharmaceutical industry with a comprehensive product portfolio. The company offers a diverse range of over-the-counter and prescription solutions, including elixirs, syrups, and semi-solids. Additionally, PAI Pharma provides a variety of packaging options such as standard bottles and ready-to-dispense unit-dose packs. Their products serve hospital, retail, and acute care markets, ensuring broad access to essential medicines.
Product Offerings
PAI Pharma boasts a broad spectrum of products, with over 250 product NDCs including unit-dose and liquid medicines. Key products include Cefotetan Powder for Injection, Prednisolone Sodium Phosphate Oral Solution, and Children's Ibuprofen Oral Suspension (Berry flavored). The company's offerings span over 50 retail items and nearly 100 unit-dose SKUs. They are also known for their extensive range of addiction treatment medications, such as methadone, buprenorphine, and naloxone-based products.
Manufacturing and Quality Assurance
PAI Pharma's manufacturing capabilities are grounded in their FDA CGMP-compliant facility. This 300,000+ sq. ft. facility in South Carolina is dedicated to oral liquid and sterile injectable products. Their commitment to quality is evident through a rigorous quality control process and world-class product safety measures. The facility operates with separate areas for manufacturing and packaging, ensuring the highest standards of efficiency and compliance with regulatory requirements such as the DEA and the 2014 Drug Supply Chain Security Act.
Acquisitions and Expansions
PAI Pharma has actively expanded its market presence through strategic acquisitions. The acquisition of VistaPharm enhanced their product offerings, especially in generic pharmaceuticals and over-the-counter products. Additionally, PAI Pharma's acquisition of Teligent Inc.’s US marketing authorizations brought over 60 generic and branded applications into their fold, further solidifying their position in the market. These include almost 50 approved products and a pipeline of over 15 additional filed products.
Distribution Network
PAI Pharma ensures the wide availability of its products through a robust distribution network that includes authorized distributors such as AmerisourceBergen, Cardinal Health, and McKesson. Products can be ordered directly from the company or from their extensive network of distributors. The company operates a maximum efficiency warehouse, ensuring compliance with DEA, FDA, and DSCSA requirements, thereby facilitating a reliable supply chain.